Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active-controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (AMG334 qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients

NCT03927144 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03927144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03927144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active-controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (AMG334 qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
May 15, 2019
Completion date
September 30, 2022
Enrollment
621 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

episodic migraine